Satellos Bioscience Inc (MSCLF)

$0.39 -0.01 (-2.10%)
Market Cap 72.29M
Revenue (ttm) 0.00
Net Income (ttm) -20.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 41,500
Avg Vol 66,652
Day's Range N/A - N/A
Shares Out 176.31M
Stochastic %K 30%
Beta 0.95
Analysts Sell
Price Target $0.86

Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
PennyScam
PennyScam Jun. 17 at 1:39 PM
$MSCLF Looking good. Crazy Kenny
0 · Reply
PennyScam
PennyScam Jun. 17 at 1:35 PM
$MSCLF Great thoughts. I’m not here for Duchenne. Couldn’t care less. I‘m here for future acquisition related to ICO Therapeutics. You know the one. I’m here for the company that they choose to ignore. It’s the company that holds all the value. I love your thoughts Flouride and Alextan. Super awesome. I’m glad people like you are on top of things. Delusional Kenny
0 · Reply
Florestan
Florestan Jun. 16 at 12:00 PM
$MSCLF today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to improving outcomes for people living with Duchenne. Satellos will be onsite to engage with the Duchenne community, listen to families’ experiences, and share updates on its science and mission to regenerate muscle from within. “We’re looking forward to connecting in person with families and advocates who are at the heart of this work,” said Frank Gleeson, Co-founder and CEO of Satellos. “This conference is a powerful reminder of why we’re focused on developing a new approach to treat Duchenne — one that aims to restore the body’s ability to repair muscle.” Attendees can meet members of the Satellos team throughout the event and learn more by visiting the company’s booth in the exhibition hall.
0 · Reply
AlexReddy2021
AlexReddy2021 Jun. 16 at 1:48 AM
$DTIL $MSCLF $SRPT
0 · Reply
Florestan
Florestan Jun. 16 at 1:33 AM
$SRPT it's also pretty clear to me at this stage that most bulls here bought after the 1st death, thinking it's some kind of generational discount. I bring the bad news. And I was mocked before for making these obvious, peer-reviewed statements, that are scientifically true. 1. Microdystrophin does not behave like normal dystrophin. They are way too short. No amount of uDystrophin is good enough. 2. Duchenne is a muscle stem cell division disease. Dumont et al. 2015 has proved this. If you don't fix that part, you can't help Duchenne patients. 3. A successful Duchenne drug must therefore either deliver dystrophin into the stem cells ($DTIL's PBGENE-DMD) or fix stem cell polarity ($MSCLF's SAT-3247). One has shown steady strength increase in mouse, the other doubled grip strength in adult patients. So good luck to all, but remember, biotech is as much luck as it is about understanding mechanism of action and science.
0 · Reply
Florestan
Florestan Jun. 10 at 4:44 PM
$MSCLF 1st half is typical presentation, 2nd half is Q&A which discuss the progress so far and what's coming in the next 3-6 months. Looking busy, and it looks like the first kid could be dosed as early as September. https://youtu.be/G71cCWWyIdg
0 · Reply
Florestan
Florestan Jun. 7 at 10:20 PM
$MSCLF Average increase of 2kg in grip strength in just 28 day of dosing, versus 1kg of increase after 48wks of treatment from exon skipping. Also notable is the age of the patient cohorts. I predict a blow out effect in the kids.
0 · Reply
Florestan
Florestan Jun. 6 at 1:31 PM
$MSCLF within 1 month of dosing, 4 patients experienced on average 5% increase in FVC. At that stage, patients typically lose 3-5% FVC a year, so they reversed a year of decline with 1 month of dosing. https://cdn-ceo-ca.s3.amazonaws.com/1k44fui-slide1.png
1 · Reply
bruceleeboy
bruceleeboy Jun. 6 at 12:32 PM
$MSCLF Gleeson knows why the stock is depressed regardless of whether he acts surprised or confused 🤪 Him and his cronies are set to make out well. As you mentioned, he’s experienced in the space and has all the connections. Fiduciary responsibility is a myth 🦄 He knows the who’s and whys of good science tanking share price. Lower sp, higher rs. Nice of them to mention BIG PHARMA’s interest. Big tell as to who is pulling the strings. Interesting they talk up-listing and merger in conjunction with Phase 2.
0 · Reply
Florestan
Florestan Jun. 4 at 12:59 PM
$MSCLF bruceleeboy what are you referring to? Gleeson sold Verio Therapeutics to FATE and after that has been working at Satellos.
0 · Reply
Latest News on MSCLF
No data available.
PennyScam
PennyScam Jun. 17 at 1:39 PM
$MSCLF Looking good. Crazy Kenny
0 · Reply
PennyScam
PennyScam Jun. 17 at 1:35 PM
$MSCLF Great thoughts. I’m not here for Duchenne. Couldn’t care less. I‘m here for future acquisition related to ICO Therapeutics. You know the one. I’m here for the company that they choose to ignore. It’s the company that holds all the value. I love your thoughts Flouride and Alextan. Super awesome. I’m glad people like you are on top of things. Delusional Kenny
0 · Reply
Florestan
Florestan Jun. 16 at 12:00 PM
$MSCLF today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to improving outcomes for people living with Duchenne. Satellos will be onsite to engage with the Duchenne community, listen to families’ experiences, and share updates on its science and mission to regenerate muscle from within. “We’re looking forward to connecting in person with families and advocates who are at the heart of this work,” said Frank Gleeson, Co-founder and CEO of Satellos. “This conference is a powerful reminder of why we’re focused on developing a new approach to treat Duchenne — one that aims to restore the body’s ability to repair muscle.” Attendees can meet members of the Satellos team throughout the event and learn more by visiting the company’s booth in the exhibition hall.
0 · Reply
AlexReddy2021
AlexReddy2021 Jun. 16 at 1:48 AM
$DTIL $MSCLF $SRPT
0 · Reply
Florestan
Florestan Jun. 16 at 1:33 AM
$SRPT it's also pretty clear to me at this stage that most bulls here bought after the 1st death, thinking it's some kind of generational discount. I bring the bad news. And I was mocked before for making these obvious, peer-reviewed statements, that are scientifically true. 1. Microdystrophin does not behave like normal dystrophin. They are way too short. No amount of uDystrophin is good enough. 2. Duchenne is a muscle stem cell division disease. Dumont et al. 2015 has proved this. If you don't fix that part, you can't help Duchenne patients. 3. A successful Duchenne drug must therefore either deliver dystrophin into the stem cells ($DTIL's PBGENE-DMD) or fix stem cell polarity ($MSCLF's SAT-3247). One has shown steady strength increase in mouse, the other doubled grip strength in adult patients. So good luck to all, but remember, biotech is as much luck as it is about understanding mechanism of action and science.
0 · Reply
Florestan
Florestan Jun. 10 at 4:44 PM
$MSCLF 1st half is typical presentation, 2nd half is Q&A which discuss the progress so far and what's coming in the next 3-6 months. Looking busy, and it looks like the first kid could be dosed as early as September. https://youtu.be/G71cCWWyIdg
0 · Reply
Florestan
Florestan Jun. 7 at 10:20 PM
$MSCLF Average increase of 2kg in grip strength in just 28 day of dosing, versus 1kg of increase after 48wks of treatment from exon skipping. Also notable is the age of the patient cohorts. I predict a blow out effect in the kids.
0 · Reply
Florestan
Florestan Jun. 6 at 1:31 PM
$MSCLF within 1 month of dosing, 4 patients experienced on average 5% increase in FVC. At that stage, patients typically lose 3-5% FVC a year, so they reversed a year of decline with 1 month of dosing. https://cdn-ceo-ca.s3.amazonaws.com/1k44fui-slide1.png
1 · Reply
bruceleeboy
bruceleeboy Jun. 6 at 12:32 PM
$MSCLF Gleeson knows why the stock is depressed regardless of whether he acts surprised or confused 🤪 Him and his cronies are set to make out well. As you mentioned, he’s experienced in the space and has all the connections. Fiduciary responsibility is a myth 🦄 He knows the who’s and whys of good science tanking share price. Lower sp, higher rs. Nice of them to mention BIG PHARMA’s interest. Big tell as to who is pulling the strings. Interesting they talk up-listing and merger in conjunction with Phase 2.
0 · Reply
Florestan
Florestan Jun. 4 at 12:59 PM
$MSCLF bruceleeboy what are you referring to? Gleeson sold Verio Therapeutics to FATE and after that has been working at Satellos.
0 · Reply
bruceleeboy
bruceleeboy Jun. 3 at 7:54 PM
$MSCLF Why? Because Gleeson and cronies are criminals that have made back alley deals to the detriment of shareholders. Investors will continue to get screwed unfortunately. The science is good. The actors are bad. I call it the Teper effect™. - Warrants exercised to keep stock around or below $.50. - As of June 2024, Satellos had approximately CA$28 million in cash with no debt. However, the company burned through CA$22 million in the previous year, representing 39% of its market capitalization at that time. This high burn rate suggests a cash runway of about 15 months, raising concerns about potential future dilution if additional funding is needed. - Company is preparing for a RS within a range of five (5) pre-consolidation shares for one (1) post-consolidation share and fifteen (15) pre-consolidation shares for one (1) post-consolidation share. Lower SP goes, higher RS will be. When the news is really good and the stock becomes depressed its 100% corruption.
1 · Reply
stevetripp
stevetripp Jun. 3 at 6:47 PM
$MSCLF WTF ? Why is this dropping??
1 · Reply
Florestan
Florestan May. 31 at 1:45 PM
$MSCLF and here are the comparisons between SAT-3247 with other drugs. The comparisons made sure that: 1. The drugs were at similar stages 2. Focus on grip strengths, so excluding drugs that haven't done such study Again, staggering.
1 · Reply
S_Franconi
S_Franconi May. 30 at 8:28 PM
$MSCLF Historical post. From June 2024 https://www.neurologylive.com/view/newly-formed-clinical-advisory-board-united-potential-sat-3247-dmd
0 · Reply
Florestan
Florestan May. 30 at 3:28 PM
$MSCLF In this DD, I've compiled a table showing SAT-3247's 1b results to competitors' "best results". In my next post I hope to compare exclusively "early" results from competitors, but the table below summarizes why one should pay attention, because significant outperformance from standard deviation is the primary early signals for blockbusters.
1 · Reply
Florestan
Florestan May. 28 at 3:57 PM
$MSCLF @bruceleeboy cheers. I believe the right time for any sort of such activity would be after proof of concept data in children.
0 · Reply
bruceleeboy
bruceleeboy May. 28 at 3:09 AM
$MSCLF @Florestan It seems they’re getting ready to up-list to Nasdaq. The $55M financing in May 2023, $40M offering in Dec 2024 and an upcoming RS will help them reach their goal. I think Nasdaq has a $4 bid price at time of listing. So right now you’re looking at an 8:1. It’ll also help them attract institutional investors while changing up the investor base. They are just waiting for the right time to trigger it imo. Cheers! Wishing you the best with this one.
0 · Reply
Florestan
Florestan May. 28 at 12:10 AM
$MSCLF that's fair @bruceleeboy, you can have your beliefs and I can have mine. The fact is they had this option for more than a year at a much weaker position and they didn't do it then, so by common sense they won't do it now. You can have a gun and not shoot.
0 · Reply
bruceleeboy
bruceleeboy May. 27 at 11:57 PM
$MSCLF @Florestan If you think the likelihood of a 15:1 RS is 0% then you haven’t just drankin’ the koolaid, you’re swimming in it. As much as I hope you’d have no RS, a zero percent chance isn’t realistic unfortunately. You guys just had some positive news and the stock actually declined. This deal like many before it, is infested with criminals. Gleason is one of them. It’s not uncommon to effect a RS/ financing on perceived good news. Watched it happen with Immune Pharmaceutical’s many times. The people and big dogs that you mentioned sitting in the cap table are already in the know and often have other arrangements made or they’ll get suckered like everyone else not in the loop. If they said they’ll do anywhere from a 5:1 (34M after) to a 15:1 (11.5M), the chances of it happening can never be zero. All this said, I think Satellos can offer more value in the future for longs like yourself; just at a fraction.
0 · Reply
Florestan
Florestan May. 27 at 11:53 PM
$MSCLF me and the gang after the kids do backflips later this year after 3 months on SAT-3247.
1 · Reply
Florestan
Florestan May. 27 at 3:52 PM
$MSCLF https://musculardystrophynews.com/news/dmd-treatment-sat-3247-safe-trial-shows-early-signs-efficacy/ $DYN $EWTX $SRPT
2 · Reply
Florestan
Florestan May. 27 at 1:19 PM
$MSCLF The likelihood of a 15:1 RS is zero burceleeboy. They had that option since spring 2024 and they did not execute it then when they had no data, why execute that now when they have dog and human data and dosing kids soon? The people that sits in the cap table include Perceptive Advisors and other big dogs. The board won't get to do an RS in a willy-nilly manner that destroy these guys' values.
0 · Reply